CalDAG-GEFI deficiency protects mice in a novel model of FcγRIIA-mediated thrombosis and thrombocytopenia
- 28 July 2011
- journal article
- Published by American Society of Hematology in Blood
- Vol. 118 (4), 1113-1120
- https://doi.org/10.1182/blood-2011-03-342352
Abstract
Platelet activation via Fcγ receptor IIA (FcγRIIA) is a critical event in immune-mediated thrombocytopenia and thrombosis syndromes (ITT). We recently identified signaling by the guanine nucleotide exchange factor CalDAG-GEFI and the adenosine diphosphate receptor P2Y12 as independent pathways leading to Rap1 small GTPase activation and platelet aggregation. Here, we evaluated the contribution of CalDAG-GEFI and P2Y12 signaling to platelet activation in ITT. Mice transgenic for the human FcγRIIA (hFcR) and deficient in CalDAG-GEFI−/− (hFcR/CDGI−/−) were generated. Compared with controls, aggregation of hFcR/CDGI−/− platelets or P2Y12 inhibitor-treated hFcR platelets required more than 5-fold and approximately 2-fold higher concentrations of a FcγRIIA stimulating antibody against CD9, respectively. Aggregation and Rap1 activation were abolished in P2Y12 inhibitor-treated hFcR/CDGI−/− platelets. For in vivo studies, a novel model for antibody-induced thrombocytopenia and thrombosis was established. FcγRIIA-dependent platelet thrombosis was induced by infusion of Alexa750-labeled antibodies to glycoprotein IX (CD42a), and pulmonary thrombi were detected by near-infrared imaging technology. Anti-GPIX antibodies dose-dependently caused thrombocytopenia and pulmonary thrombosis in hFcR-transgenic but not wild-type mice. CalDAG-GEFI-deficient but not clopidogrel-treated hFcR-transgenic mice were completely protected from ITT. In summary, we established a novel mouse model for ITT, which was used to identify CalDAG-GEFI as a potential new target in the treatment of ITT.Keywords
This publication has 41 references indexed in Scilit:
- The kinetics of αIIbβ3 activation determines the size and stability of thrombi in mice: implications for antiplatelet therapyBlood, 2011
- CalDAG-GEFI is at the nexus of calcium-dependent platelet activationBlood, 2009
- CalDAG-GEFI and protein kinase C represent alternative pathways leading to activation of integrin αIIbβ3 in plateletsBlood, 2008
- Mice lacking the signaling molecule CalDAG-GEFI represent a model for leukocyte adhesion deficiency type IIIJCI Insight, 2007
- Prothrombotic factors enhance heparin‐induced thrombocytopenia and thrombosis in vivo in a mouse modelJournal of Thrombosis and Haemostasis, 2006
- Heparin‐induced thrombocytopenia and thrombosisAmerican Journal of Hematology, 2005
- Immune heparin-induced thrombocytopenia can occur in patients receiving clopidogrel and aspirinAmerican Journal of Hematology, 2005
- Clinical features of heparin-induced thrombocytopenia including risk factors for thrombosisThrombosis and Haemostasis, 2005
- The role of CD40 in CD40L- and antibody-mediated platelet activationThrombosis and Haemostasis, 2005
- Immune ThrombocytopeniaThe New England Journal of Medicine, 1979